Perturbation of Cellular Translation and RNA Metabolism by SARS-COV-2 Nucleoprotein Phase Separation

SARS-COV-2 核蛋白相分离对细胞翻译和 RNA 代谢的干扰

基本信息

  • 批准号:
    10354076
  • 负责人:
  • 金额:
    $ 7.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-11-01 至 2023-10-31
  • 项目状态:
    已结题

项目摘要

This proposal will investigate the role severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N protein phase separation in disrupting cellular translation and RNA metabolism. N protein phase separation creates membraneless organelles and concentrates RNAs in a droplet (dense) phase. While N protein is responsible for encapsidation of the viral genome, N protein also binds hundreds of host messenger RNAs, some of which are necessary for translation and nonsense-mediated decay (NMD). NMD targets diverse families of RNA viruses for RNA decay, including betacoronaviruses, and the N protein from Murine hepatitis virus (MHV) interferes with NMD during the early stages of infection. Since NMD targets 10% of cellular transcripts for degradation, inhibition by N protein likely has profound effects on the host cell transcriptome. While the mechanism underlying the inhibition of NMD by N protein remains unclear, phase separation and translational repression by N could be a predominant factor. The cellular proteins FUS and C9orf72 arginine- rich dipeptide repeats are known to phase separate, repress translation, inhibit NMD, and are associated with Amyotrophic lateral sclerosis (ALS) disease progression. Viral proteins, including N protein, may repress the translation of transcripts necessary for the co-translational NMD pathway, potentially shaping the host transcriptome in a way that favors virus replication. Recent work has shown that SARS-CoV-2 infection induces high expression of inflammatory cytokines but fails to mount a robust interferon response. The underlying factors driving these transcriptional responses remain unknown; however, N protein could provoke this response by interfering with NMD and blocking post-transcriptional regulation. This project will use transcriptome-wide ribosome profiling (Ribo-seq) to identify cellular transcripts that are translationally repressed by N protein. Previously identified NMD targets will be examined to determine if translational repression confers NMD-resistance. Phase-separation deficient N mutants will be expressed in parallel to determine whether phase separation is the driving force in translation and NMD inhibition. Finally, the results generated from this study will be cross-referenced with published RNA-seq datasets from SARS-CoV-2 infected cells to determine the extent that N protein contributes to the large-scale changes in gene expression during infection. These findings will better our understanding of the virus-host interactions that take place during SARS-CoV-2 infection and will support on-going vaccine and antiviral development, especially N-based approaches.
这项建议将研究严重急性呼吸综合征冠状病毒2(SARS-CoV-2)N蛋白相分离在扰乱细胞翻译和RNA代谢中的作用。N蛋白相分离产生无膜细胞器,并将RNA浓缩在液滴(密集)相中。虽然N蛋白负责病毒基因组的封装,但N蛋白也结合了数百个宿主信使RNA,其中一些是翻译和无意义介导的衰变(NMD)所必需的。NMD针对不同的RNA病毒家族进行RNA衰变,包括贝塔冠状病毒,而来自小鼠肝炎病毒(MHV)的N蛋白在感染的早期阶段干扰NMD。由于NMD针对10%的细胞转录物进行降解,N蛋白的抑制可能会对宿主细胞转录组产生深远的影响。虽然N蛋白抑制NMD的机制尚不清楚,但N蛋白的相分离和翻译抑制可能是主要因素。细胞蛋白FUS和C9orf72富含精氨酸的二肽重复序列已知可以进行时相分离、抑制翻译、抑制NMD,并与肌萎缩侧索硬化症(ALS)的疾病进展有关。病毒蛋白,包括N蛋白,可能抑制共翻译NMD途径所需的转录本的翻译,潜在地以一种有利于病毒复制的方式塑造宿主转录组。最近的研究表明,SARS-CoV-2感染诱导了炎性细胞因子的高表达,但未能启动强大的干扰素反应。驱动这些转录反应的潜在因素尚不清楚;然而,N蛋白可能通过干扰NMD和阻断转录后调节来引发这种反应。该项目将使用转录组范围的核糖体图谱(Ribo-seq)来识别被N蛋白翻译抑制的细胞转录本。将检查以前确定的NMD目标,以确定翻译抑制是否具有NMD抵抗力。将平行表达相分离缺陷的N突变体,以确定相分离是否是翻译和NMD抑制的驱动力。最后,这项研究产生的结果将与已发表的来自SARS-CoV-2感染细胞的RNA-seq数据集进行交叉参考,以确定N蛋白在感染过程中对基因表达的大规模变化的贡献程度。这些发现将使我们更好地了解SARS-CoV-2感染期间发生的病毒-宿主相互作用,并将支持正在进行的疫苗和抗病毒开发,特别是基于N的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jared Paul May其他文献

Jared Paul May的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jared Paul May', 18)}}的其他基金

Perturbation of Cellular Translation and RNA Metabolism by SARS-COV-2 Nucleoprotein Phase Separation
SARS-COV-2 核蛋白相分离对细胞翻译和 RNA 代谢的干扰
  • 批准号:
    10516080
  • 财政年份:
    2021
  • 资助金额:
    $ 7.83万
  • 项目类别:
Non-canonical translation in plant and animal (+)-strand viruses
植物和动物 ( ) 链病毒中的非规范翻译
  • 批准号:
    9121934
  • 财政年份:
    2016
  • 资助金额:
    $ 7.83万
  • 项目类别:
Non-canonical translation in plant and animal (+)-strand viruses
植物和动物 ( ) 链病毒中的非规范翻译
  • 批准号:
    9268438
  • 财政年份:
    2016
  • 资助金额:
    $ 7.83万
  • 项目类别:

相似海外基金

Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
  • 批准号:
    MR/Y014901/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.83万
  • 项目类别:
    Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
  • 批准号:
    MR/Y014286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.83万
  • 项目类别:
    Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
  • 批准号:
    MR/Y503502/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.83万
  • 项目类别:
    Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
  • 批准号:
    2317745
  • 财政年份:
    2023
  • 资助金额:
    $ 7.83万
  • 项目类别:
    Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
  • 批准号:
    10759808
  • 财政年份:
    2023
  • 资助金额:
    $ 7.83万
  • 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
  • 批准号:
    10606865
  • 财政年份:
    2023
  • 资助金额:
    $ 7.83万
  • 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
  • 批准号:
    10696512
  • 财政年份:
    2023
  • 资助金额:
    $ 7.83万
  • 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
  • 批准号:
    10848139
  • 财政年份:
    2023
  • 资助金额:
    $ 7.83万
  • 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
  • 批准号:
    MR/Y001095/1
  • 财政年份:
    2023
  • 资助金额:
    $ 7.83万
  • 项目类别:
    Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
  • 批准号:
    488892
  • 财政年份:
    2023
  • 资助金额:
    $ 7.83万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了